Vasopressin receptor antagonists in patients with chronic heart failure.

Abstract

In this brief review, the pathophysiology of hyponatremia and its clinical significance in the course of chronic heart failure (CHF) are illustrated. Moreover, issues concerning the optimal treatment for hyponatremia during CHF are addressed and discussed. In addition, advantages and limitations resulting from the use of vasopressin receptor antagonists, drugs that have recently emerged as the best available resource against hyponatremia, are highlighted.

• Authors: R De Vecchis, C Cantatrione, D Mazzei
• Journal: Herz (Herz) Vol. 42 Issue 5 Pg. 492-497 (Aug 2017) ISSN: 1615-6692 [Electronic] Germany
• Vernacular Title: Vasopressinrezeptorantagonisten bei Patienten mit chronischer Herzinsuffizienz.
• PMID: 27628642 (Publication Type: Comparative Study, Journal Article, Review)

Chemical References

• Antidiuretic Hormone Receptor Antagonists
• Arginine Vasopressin
• Sodium

Topics

• Antidiuretic Hormone Receptor Antagonists (adverse effects, therapeutic use)
• Arginine Vasopressin (blood)
• Chronic Disease
• Extracellular Fluid (drug effects, physiology)
• Heart Failure (drug therapy, physiopathology)
• Humans
• Hyponatremia (drug therapy, physiopathology)
• Sodium (blood)
• Water-Electrolyte Balance (drug effects, physiology)